Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Sees Large Volume Increase – What’s Next?

Shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) saw an uptick in trading volume on Tuesday. 3,597,782 shares traded hands during trading, an increase of 403% from the previous session’s volume of 715,173 shares. The stock last traded at $21.2810 and had previously closed at $21.94.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on FMS. Weiss Ratings raised shares of Fresenius Medical Care AG & Co. KGaA from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, October 8th. Zacks Research cut shares of Fresenius Medical Care AG & Co. KGaA from a “hold” rating to a “strong sell” rating in a research note on Thursday, October 15th. Sanford C. Bernstein raised their price objective on shares of Fresenius Medical Care AG & Co. KGaA from $25.50 to $25.80 and gave the stock a “market perform” rating in a report on Thursday, August 6th. Berenberg Bank set a $24.00 price objective on shares of Fresenius Medical Care AG & Co. KGaA in a report on Tuesday, September 29th. Finally, BNP Paribas Exane lowered shares of Fresenius Medical Care AG & Co. KGaA from a “neutral” rating to an “underperform” rating and set a $19.90 price objective for the company. in a research note on Tuesday, July 28th. Seven investment analysts have rated the stock with a Hold rating and four have issued a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Reduce” and an average price target of $23.42.

Fresenius Medical Care AG & Co. KGaA Price Performance

The business’s 50-day moving average price is $22.51 and its 200 day moving average price is $22.87. The company has a market capitalization of $11.58 billion, a P/E ratio of 8.05, a price-to-earnings-growth ratio of 4.97 and a beta of 0.74. The company has a quick ratio of 0.75, a current ratio of 1.07 and a debt-to-equity ratio of 0.43.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last posted its earnings results on Monday, August 3rd. The company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.62 by $0.04. Fresenius Medical Care AG & Co. KGaA had a net margin of 4.83% and a return on equity of 9.28%. The business had revenue of $5.55 billion for the quarter, compared to analyst estimates of $5.48 billion. Analysts anticipate that Fresenius Medical Care AG & Co. KGaA will post 2.25 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Mather Group LLC. raised its position in shares of Fresenius Medical Care AG & Co. KGaA by 838.0% in the third quarter. Mather Group LLC. now owns 1,407 shares of the company’s stock worth $31,000 after buying an additional 1,257 shares in the last quarter. Farther Finance Advisors LLC boosted its stake in Fresenius Medical Care AG & Co. KGaA by 39.1% during the third quarter. Farther Finance Advisors LLC now owns 1,915 shares of the company’s stock valued at $43,000 after buying an additional 538 shares during the period. Allworth Financial LP boosted its stake in Fresenius Medical Care AG & Co. KGaA by 31.5% during the second quarter. Allworth Financial LP now owns 3,552 shares of the company’s stock valued at $80,000 after buying an additional 850 shares during the period. Integrated Wealth Concepts LLC purchased a new position in Fresenius Medical Care AG & Co. KGaA during the second quarter worth about $91,000. Finally, EverSource Wealth Advisors LLC grew its position in Fresenius Medical Care AG & Co. KGaA by 50.3% during the first quarter. EverSource Wealth Advisors LLC now owns 4,135 shares of the company’s stock worth $93,000 after buying an additional 1,383 shares in the last quarter. 8.37% of the stock is currently owned by hedge funds and other institutional investors.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is a Germany-based health care company focused on the treatment of chronic kidney failure. The company provides dialysis care for patients with end-stage renal disease through a network of outpatient dialysis clinics and other health care facilities.

In addition to operating dialysis centers, Fresenius Medical Care develops and supplies products used in dialysis treatment. Its portfolio includes hemodialysis machines, dialyzers, dialysis solutions, bloodlines, and related medical devices and services.